

**PCT**WORLD INTELLECTUAL PROPERTY  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER

NO 9607431A1

(51) International Patent Classification <sup>6</sup> : <b>A61K 41/00, C07D 311/82</b>		<b>A1</b>	(11) International Publication Number: <b>WO 96/07431</b>
			(43) International Publication Date: 14 March 1996 (14.03.96)
(21) International Application Number: <b>PCT/CA95/00485</b>		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: 16 August 1995 (16.08.95)		Published <i>With international search report.</i>	
(30) Priority Data: 08/300,179                      2 September 1994 (02.09.94)      US			
(71) Applicant: UNIVERSITE DE MONTREAL [CA/CA]; 2900 Edouard-Montpetit, Montréal, Québec H3T 1J4 (CA).			
(72) Inventors: GABOURY, Louis; 5624 Canterbury, Montréal, Québec H2W 1T8 (CA). GIASSEN, Richard; 4333 Earncliffe, Montréal, Québec H4A 3E9 (CA). LI, Tiechao; 2880 Goyer Street #9, Montréal, Québec H3S 1H3 (CA). GUPTA, Ajay. Kumar; 55 Lakeshore Drive #101, Pointe Claire, Québec H9S 4H4 (CA). VILLENEUVE, Luc; 2117 boulevard St-Joseph Est, Montréal, Québec H2H 1E6 (CA).			
(74) Agent: CÔTÉ, France; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).			
(54) Title: NOVEL RHODAMINE DERIVATIVES FOR PHOTODYNAMIC THERAPY OF CANCER AND IN VITRO PURGING OF THE LEUKEMIAS			
(57) Abstract			
<p>The present invention relates to novel photoactivable rhodamine derivatives for enhancing high quantum-yield production and singlet oxygen generation upon irradiation with light while maintaining desirable differential retention of rhodamine between normal and cancer cells, said derivatives are selected from the group consisting of 4,5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrochloride); 4,5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid ethyl ester hydrochloride); 4,5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid octyl ester hydrochloride); 4,5-dibromorhodamine 110 n-butyl ester (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride); Rhodamine B n-butyl ester (2-(6-ethyl amino-3-ethyl imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride); and photoactivable derivatives thereof; whereby photoactivation of the derivatives induces cell killing while unactivated derivatives are substantially non-toxic to cells. Also, the present invention relates to the use of the photoactivable derivatives of the present invention for the photodynamic therapy of a cancer patient by destroying human cancer cells, wherein appropriate intracellular levels of the derivatives are achieved and irradiation with light of a suitable wavelength is applied. The present invention also relates to a method for the photodynamic therapy of a patient suffering from leukemias, disseminated multiple myelomas or lymphomas.</p>			

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

WO 96/07431

PCT/CA95/00485

**NOVEL RHODAMINE DERIVATIVES FOR PHOTODYNAMIC THERAPY  
OF CANCER AND IN VITRO PURGING OF THE LEUKEMIAS**

**BACKGROUND OF THE INVENTION**

5 (a) Field of the Invention

The invention relates to a photodynamic treatment for the selective destruction of malignant leukemic cells without affecting the normal cells and without causing systemic toxicity for the patient.

10 (b) Description of Prior Art

Cancers are uncontrolled cell proliferations that result from the accumulation of genetic changes in cells endowed with proliferative potential. After a variable latency period during which they are clinically silent, the malignant cells progress to aggressive invasive and metastatic stages with tumor formation, bleeding, susceptibility to infections, and widespread dissemination throughout the body.

20 Despite important advances in treatment, cancers still account for 28% of death in Western countries. Treatment of cancer has relied mainly on surgery, chemotherapy, radiotherapy and more recently immunotherapy. Significant improvement in outcome has  
25 occurred with the use of combined modalities, for a small number of cancers. However, for the most frequent types of cancers (lung, breast, colo-rectal and the leukemias) complete remission and cure has not been achieved. Therefore, the development of new  
30 approaches for treating cancer patients is critically needed particularly for those patients whose disease has progressed to a metastatic stage and are refractory to standard chemotherapy. To overcome resistance, autologous stem cell transplantation  
35 (AuSCT) has been employed in the treatment of a number of advanced forms of cancer. Because high-dose

WO 96/07431

PCT/CA93/00485

- 2 -

chemotherapy with or without total body irradiation can be applied prior to AuSCT, increased response rates have been observed when compared with standard chemotherapy. One important issue that needs to be stressed when using AuSCT relates to the risk of reinfusing residual tumor cells despite histologic remission. A variety of techniques have been developed that can deplete up to  $10^5$  of tumor cells from the marrow. These techniques, including immunologic and pharmacologic purging, are not entirely satisfactory. One major consideration when purging bone marrows is to preserve the normal hemopoietic stem cell compartment so that normal hemopoiesis can rapidly become reestablished upon grafting. The potential of photodynamic therapy, in association with photosensitizing molecules capable of destroying malignant cells while sparing normal hemopoietic stem cells, to purge bone marrow in preparation for AuSCT has largely been unexplored. This issue has been investigated in depth for one type of neoplasm, chronic myeloid leukemia (CML), since AuSCT has the potential to cure the disease and highly sensitive molecular biologic techniques are currently available to determine the efficacy of the purging procedure. Application of photodynamic therapy for treating other forms of leukemias, lymphomas and metastatic solid tumors is a distinct possibility in view of the functional properties of the dyes molecules which were synthesized in accordance with the present invention and whose description appears below.

Chronic myeloid leukemia (CML) comprises 15% of the leukemias. It is a clonal pluripotent hemopoietic stem cell disorder characterized by deregulated proliferation of bone marrow progenitors and

WO 96/07431

PCT/CA93/00485

- 3 -

circulating terminally differentiated myeloid cells. If left untreated this disease is invariably fatal.

Genetic analysis on CML cells has identified a highly characteristic abnormality consisting of a balanced translocation involving chromosome 9 and 22 where part of the c-abl protooncogene on chromosome 9 is juxtaposed to the 5' end of the bcr-1 gene on chromosome 22, leading to the formation of a fusion gene, a chimeric transcript and a P210 bcr/abl protein with tyrosine kinase activity. CML cells harboring the translocation are known as Ph-1+ cells, whereas non-clonal, presumably normal but suppressed marrow cells are known as Ph-1 negative (Ph-1-) cells.

Treatment of CML patient aims at eradicating Ph-1+ cells and reestablishing non-clonal Ph-1-hemopoiesis. Conventional myelosuppressive therapy with hydroxyurea, busulfan, and more recently with interferon-alpha (IFN-alpha) and hemoharringtonine (HTT) have failed to provide prolonged or complete clinical and cytogenetic remissions (reviewed in Goldman J.M. (1994) *Blood Reviews*, 8:21-29). To date, only allogenic bone marrow transplantation (ABMT) in young patients (<55 years) with human leukocyte antigen-compatible (HLA-compatible) siblings donor marrow has been shown to be curative in over 50% of good risks patients. However, only a minority of patients (20%) is eligible for allogenic bone marrow transplantation because of the lack of suitably matched donors or because patients are deemed too old to withstand the procedure. Therefore, alternative strategies to treat CML had to be developed. One promising line of research that has produced exciting results consists of restoring Ph- hemopoiesis by grafting patient's own marrow or peripheral blood stem cells that were harvested in chronic phase prior to

WO 96/07431

PCT/CA95/00485

- 4 -

intensive chemotherapy and total body irradiation. This procedure, known as autologous stem cell transplantation (AuSCT) involves, no or some ex vivo marrow manipulations to purge residual malignant Ph+ leukemic cells. To achieve eradication of the Ph-1+ clone several approaches have been proposed including:

- 1) in vitro exposure of the graft to 4-perhydroxycyclophosphamide (4-HC) or to a more stable derivative Mafosfamide™ (Asta-Z 7557);
- 2) in vitro selection by growth in long-term culture;
- 3) positive selection of CD34+DR- non-clonal stem cells; and
- 4) in vivo therapy with combinations of antileukemic agents or with interferon-alpha followed by transplant.

However, the clinical relevance of these methods remains to be established.

There are many reports on the use of photodynamic therapy in the treatment of malignancies (Daniell M. D., Hill J. S. (1991) *Aust. N. Z. J. Surg.*, 61: 340-348). The method has been applied for cancers of various origins and more recently for the eradication of viruses and pathogens (Raab O. (1900) *Infusoria Z. Biol.*, 39: 524).

The initial experiments on the use photodynamic therapy for cancer treatment using various naturally occurring or synthetically produced photoactivable substances were published early this century (Jesionek A., Tappeiner V.H. (1903) *Muench Med Wochneshr*, 47: 2042; Hausman W. (1911) *Biochem. Z.*, 30: 276). In the 40's and 60's, a variety of tumor types were subjected to photodynamic therapy both in vitro and in vivo (Kessel, David (1990) *Photodynamic Therapy of neoplastic disease*, Vol. I, II, CRC Press. David

WO 96/07431

PCT/CA95/00485

- 5 -

Kessel, Ed. ISBN 0-8493-5816-7 (v. 1), ISBN 0-8493-5817-5 (v. 2)). Dougherty et al. and others, in the 70's and 80's, systematically explored the potential of oncologic application of photodynamic therapy  
5 (Dougherty T. J. (1974) *J. Natl Cancer Inst.*, 51: 1333-1336; Dougherty T. J. et al. (1975) *J. Natl Cancer Inst.*, 55: 115-121; Dougherty T. J. et al. (1978) *Cancer Res.*, 38: 2628-2635; Dougherty T. J. (1984) *Urol. Suppl.*, 23: 61; Dougherty T. J. (1987)  
10 *Photochem. Photobiol.*, 45: 874-889).

#### Treatment of leukemia with photodynamic therapy

There is currently a lack of antineoplastic agents which allow selective destruction of expanded  
15 leukemic cells while leaving intact the normal but suppressed residual cellular population. Preferential uptake of photosensitive dye and cytotoxicity of photodynamic therapy against leukemia cells have been previously demonstrated (Jamieson C. H. et al. (1990)  
20 *Leuk. Res.*, 14: 209-219).

It would be highly desirable to be provided with new photosensitizers which possess the following characteristics:

- 25 i) preferential localization and uptake by the malignant cells;
- ii) upon application of appropriate light intensities, killing those cells which have accumulated and retained the photosensitizing agents;
- 30 iii) sparing of the normal hemopoietic stem cell compartment from the destructive effects of activated photosensitizers; and
- iv) potential utilization of photosensitizers for bone marrow purging of harvested marrow in

WO 96/07431

PCT/CA95/00485

- 6 -

preparation for autologous bone marrow transplantation.

#### The Rhodamine dyes

5 Rhodamine 123 (2-(6-amino-3-imino-3H-xanthen-9-yl) benzoic acid methyl ester hydrochloride), a lipophilic cationic dye of the pyrylium class which can disrupt cellular homeostasis and be cytostatic or cytotoxic upon high concentration exposure and/or  
10 photodynamic therapy, although with a very poor quantum yield (Darzynkiewicz Z., Carter S. (1988) *Cancer Res.*, 48: 1295-1299). It has been used in vitro as a specific fluorescent stain for living mitochondria. It is taken up and is preferentially  
15 retained by many tumor cell types, impairing their proliferation and survival by altering membrane and mitochondrial function (Oseroff A. R. (1992) *In Photodynamic therapy* (Henderson B. W., Dougherty T. J., eds) New York: Marcel Dekker, pp. 79-91). In vivo, chemotherapy with rhodamine 123 can prolong the  
20 survival of cancerous mice, but, despite initial attempts to utilize rhodamine 123 in the treatment of tumors, its systemic toxicity of rhodamine 123 may limit its usefulness (Bernal, S.D., et al. (1983) *Science*, 222: 169; Powers, S.K. et al. (1987) *J. Neurosur.*, 67: 889).

United States Patent No. 4,612,007 issued on September 16, 1986 in the name of Richard L. Edelson, discloses a method for externally treating human  
30 blood, with the objective of reducing the functioning lymphocyte population in the blood system of a human subject. The blood, withdrawn from the subject, is passed through an ultraviolet radiation field in the presence of a dissolved photoactive agent capable of  
35 forming photoadducts with lymphocytic-DNA. This



WO 96/07431

PCT/CA95/00485

- 7 -

method presents the following disadvantages and deficiencies. The procedure described is based on the utilization of known commercially available photoactive chemical agents for externally treating patient's blood, leaving the bone marrow and potential resident leukemic clones intact in the process. According to Richard L. Edelson, the method only reduces, does not eradicate, the target cell population. Moreover, the wavelength range of UV radiation used in the process proposed by Richard L. Edelson could be damageable to the normal cells.

International Application published on January 7, 1993 under International publication number WO 93/00005, discloses a method for inactivating pathogens in a body fluid while minimizing the adverse effects caused by the photosensitive agents. This method essentially consists of treating the cells in the presence of a photoactive agent under conditions that effect the destruction of the pathogen, and of preventing the treated cells from contacting additional extracellular protein for a predetermined period of time. This method is concerned with the eradication of infectious agents from collected blood and its components, prior to storage or transfusion, and does not impede on the present invention.

It would be highly desirable to be provided with a new approach for the use of rhodamine derivatives in the treatment of tumors which overcomes these drawbacks while having no systemic toxicity for the patient.

WO 96/07431

PCT/CA95/00485

- 8 -

# SUMMARY OF THE INVENTION

Since autologous stem cell transplantation (AuSCT) offers a potentially curative strategy if normal hematopoietic cells could be separated from neoplastic stem cells either *in vitro* or *in vivo*, the possibility was investigated, of using photosensitizing dyes with high quantum efficiencies of phototoxic activity in combination with photodynamic therapy (PDT) to achieve selective eradication of the Ph-1+ leukemic cells. In sharp contrast with isolated reports describing PDT-based purging of marrow using merocyanine-sensitized photoinactivation, the molecules of the present invention were designed to take advantage of the known exclusion of rhodamine-123 and its derivatives (personal observations) from normal hemopoietic stem cells which stain poorly with rhodamine 123 and yet maintain extensive self-renewal *in vitro*. Moreover, because PDT-based bone marrow purging does not preclude the use of other means of effecting positive and/or negative selection of marrows it could be used in conjunction with other therapeutic regimens.

One aim of the present invention is to produce new photosensitizers endowed with the following characteristics:

- i) preferential localization and uptake by the malignant cells;
- ii) upon application of appropriate light intensities, killing those cells which have accumulated and retained the photosensitizing agents;
- iii) sparing of the normal hemopoietic stem cell compartment from the destructive effects of activated photosensitizers; and

WO 96/07431

PCT/CA95/00485

- 9 -

iv) potential utilization of photosensitizers for bone marrow purging of harvested marrow in preparation for autologous bone marrow transplantation.

5 Accordingly, the method of the present invention using photodynamic therapy was structured so as to eradicate the malignant clonogenic cells from CML bone marrow.

10 Another aim of the present invention is to provide, using rhodamine derivatives, a new method for the treatment of tumors which overcomes the systemic toxicity problems, inasmuch as photodynamic therapy is used *in vitro* for the purging of cancerous clones from the bone marrow of chronic myelogenous leukemia (CML)  
15 patients.

In accordance with the present invention, the phototoxicity of rhodamine B n-butylester (2-(6-ethyl amino-3-ethyl imino-3H-xanthen-9-yl) benzoic acid n-butyl ester hydrochloride), 4,5-dibromorhodamine 110  
20 n-butyl ester (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl) benzoic acid n-butyl ester hydrochloride) and 4,5-dibromorhodamine 110 n-butyl ester (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl) benzoic acid methyl ester hydrochloride) and other  
25 esters (ethyl, octyl) have been assessed.

In accordance with the present invention, there is provided photoactivable rhodamine derivatives for enhancing high quantum-yield production and singlet oxygen generation upon irradiation while maintaining  
30 desirable differential retention of rhodamine between normal and cancer cells, said derivatives are selected from the group consisting of 4,5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrochloride); 4, 5-  
35 dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-

WO 96/07431

PCT/CA95/00485

- 10 -

3H-xanthen-9-yl)-benzoic acid ethyl ester hydrochloride); 4, 5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid octhyl ester hydrochloride); 4,5-dibromorhodamine 110 n-butyl ester (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride); Rhodamine B n-butyl ester (2-(6-ethyl amino-3-ethyl imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride); and photoactivable derivatives thereof; whereby photoactivation of said derivatives induces cell killing while unactivated derivatives are substantially non-toxic to cells.

In accordance with the present invention, the complete growth inhibition of tumor cell lines is achieved *in vitro* after photodynamic therapy effected with the above-mentioned photosensitizers. This effect contrasts with the lack of inhibitory effect upon exposure to either light alone or to a saturating concentration of the photosensitizers.

Due to the specific retention of the rhodamine 123 class of dyes by the abnormal malignant cells and the concomitant lack of their accumulation by the normal hematopoietic stem cells, these results provide evidence for the potential use of these three new dyes for *in vivo* or *in vitro* photodynamic therapy.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 is a graph of the photo toxicity of 4,5-dibromorhodamine 123 used in accordance with the method of the present invention and expressed in % viability;

Figs. 2A, 2B and 2C show three graphs of the photo toxicity of 4,5-dibromorhodamine 110 n-butyl ester used in accordance with the method of the present invention and expressed in % viability; and

WO 96/07431

PCT/CA95/00485

- 11 -

Figs. 3A and 3B show two graphs of the photo toxicity of rhodamine B n-butyl ester used in accordance with the method of the present invention and expressed in % viability.

5

#### DETAILED DESCRIPTION OF THE INVENTION

Photoactive dyes are excited from the ground state to the singlet excited state following absorption of photons. Singlet excited states of organic molecules generally have short lifetimes ( $10^{-12}$ - $10^{-6}$  sec.) as they rapidly relax back to the ground state using non-radiative (vibrational modes) and radiative (fluorescence) processes. Intersystem crossing to the more stable triplet excited state is also competing with relaxation to the ground state. Triplet excited states generally have longer lifetimes ( $10^{-6}$ - $10$  sec) which allow them to diffuse and react with other molecules in the medium.

Reactivity between molecular oxygen and a photosensitizer excited to the triplet state, both present in malignant cells, is the operating principle of most photodynamic therapies. Triplet excited states can react with molecular oxygen via two different mechanisms. The first mechanism (Type I) consists of the transfer of an electron from the excited dyes to molecular oxygen, resulting in highly reactive free radicals being present in the cellular environment.

The second mechanism (Type II) consists of the transfer of energy from the excited dyes to molecular oxygen, leading to the formation of cytotoxic singlet oxygen.

Photosensitizers must therefore meet two conditions in order to be an effective phototherapeutic agent. The first condition is that

WO 96/07431

PCT/CA95/00485

- 12 -

they must be present at a far higher concentration in malignant cells than that in normal cells. A higher concentration of dyes in malignant cells results in a higher concentration of photogenerated cytotoxic species and therefore in a higher death rate. The second condition is that irradiation of the phototherapeutic agent, in the presence of intracellular concentrations of molecular oxygen, must lead to the formation of the cytotoxic species with high efficiency.

Rhodamine 123 is known to be taken up and preferentially retained by many tumor cells and consequently its use as a phototherapeutic agent has been proposed. However, the singlet excited state of Rhodamine 123 does not undergo intersystem crossing to the triplet excited state efficiently. Because of this, Rhodamine 123 is a weak phototoxin (Morliere, P et al. (1990) *Photochemistry and Photobiology*, 52(4): 703-710).

To overcome the limitations of the prior art methods, the chemical structure of rhodamine 123 can be modified in such a way as to enhance intersystem crossing to the triplet excited state. Theoretically, this could be achieved by substituting heavy atoms, such as Br or other halides, for hydrogen atoms in the molecular structure of rhodamine 123. Therefore, dibromorhodamine 123 has been prepared and tested.

The amphiphatic structure and hydrophilicity of the dyes could modulate the cytoplasmic and mitochondrial membranes and affect the phototoxicity of the dye. For example, hydrophobicity was shown to be the most important factor influencing the *in vitro* uptake of porphyrins (Chi-Wei Lin (1990) *In Photodynamic therapy of neoplastic disease*, Vol II, CRC Press, pp 79-101). Therefore, different esters of

WO 96/07431

PCT/CA95/00485

- 13 -

rhodamine 123 and rhodamine B were prepared and tested. More specifically dibromorhodamine n-butyl ester (DBBE) and rhodamine B n-butyl-ester (RBBE).

5 Different heavy atom substitutions of the hydrogen atoms (halogenic substitution) of the rhodamine backbone, for example, dibromo and diiodo derivatives of rhodamine B and Rh 110, are being prepared and tested.

10 Dimers/oligomers, hetero dimers/oligomers of such compounds also will be prepared and tested.

Substitution of the oxygen heteroatom of the rhodamine backbone by a heavier atom to reduce  $S_0/S_1$  splitting, theoretically should increase spin orbit coupling and promote intersystem crossing from the  $S_1$  to the  $T_1$  state, producing higher triplets yields than the original dye. This should increase proportionally the production of singlet oxygen. Therefore, S (Sulfur), Se (Selenium) and Te (Tellurium) substitutions for the oxygen atom (O) of the rhodamine backbone is explored. More over, other strategies for increasing high quantum yields of Type I (free radicals) or Type II (superoxyde anion or singlet oxygen) products and tumor selective accumulation of the dye are tested.

25 In accordance with the present invention, there is provided the use of such above-mentioned dyes in conjugation with tumor specific antibodies, or poisonous substances, or liposomal or lipoproteins, or fluorochrome adducts.

30 In addition, the photosensitizers to be described have the potential to act synergistically in conjunction with other photoactive substances.

Moreover, the negative selection procedure provided by the use of photodynamic treatment does not preclude the use of other means for enriching

WO 96/07431

PCT/CA95/00485

- 14 -

hematopoietic stem cells such as positive selection with anti-CD34 monoclonal antibodies.

#### Other Clinical applications


5 In addition to using photosensitizers in the context of *in vitro* bone marrow purging for the leukemias and metastatic cancers, the molecules can also be used *in vivo* for tumor sites directly accessible to exposure to a light source and to  
10 appropriate local concentrations of the drugs to be described.

#### Chemical Synthesis

All flash chromatography was done according to  
15 the method of Still et al. (Still W. C. et al. (1978) *J. Org. Chem.*, **43**: 2923). Thin-layer chromatography was conducted on silica Gel 60™ (HF-245, E. Merck) at a thickness of 0.20mm. Nuclear magnetic resonance spectra were obtained with a Varian VXR 300™ (300MHz)  
20 instrument. Spectral data are reported in the following order: chemical shift (ppm), multiplicity, coupling constants, number of proton, assignment. Low resolution mass spectra using fast atom bombardment (FAB), were obtained on a Kratos MS-50 TA™  
25 spectrometer. Ultraviolet spectra were obtained on a Varian DMS100™ spectrophotometer and data are presented as  $\lambda_{\text{max}}$ .

#### 1. Preparation of rhodamine B n-butylester

30





WO 96/07431

PCT/CA95/00485

- 15 -

Rhodamine B hydrochloride (150 mg, 0.31 mmol) was dissolved in 1-butanol (5 ml). The reaction mixture was saturated with HCl (gas) and then stirred at 100°C for 15 hr. 1-Butanol was evaporated under reduced pressure. The crude oily residue was purified by flash chromatography using CH<sub>2</sub>Cl<sub>2</sub> (200 ml) and then CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH (85:15) as eluant yielding 142 mg (0.27 mmol, 87% yield) of a dark red solid.

10


<sup>1</sup>H NMR (Varian 300 MHz, Acetone, TMS)

δ 8.31 (dd, J=1.4 and 7.8Hz, 1H); 7.86-7.94 (M, 2H); 7.54 (dd, J=1.5 and 7.4Hz, 1H); 7.14-7.23 (M, 4H); 7.02 (d, J=2.2Hz, 2H); 3.97 (t, J=6.3Hz, 2H); 3.79 (q, J=7.1Hz, 8H); 1.32 (t, J=7.1Hz, 12H); 1.2-1.4 (M, 2H); 1.01 (h, J=7.5Hz, 2H); 0.75 (h, J=7.3Hz, 3H).

15

UV (methanol) /<sub>max</sub>: 545nm

## 2. Preparation of dibromorhodamine n-butylester



### 5 2.1 Preparation of rhodamine n-butylester

Rhodamine 110 (14 mg, 0.038 mmol) was dissolved in 1-butanol (5 ml). The reaction mixture was saturated with HCl (gas) and then stirred at 100°C for 15 hr. The 1-Butanol was evaporated under reduced pressure. The crude oily residue was purified by flash chromatography using  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$  (85:15) as eluant yielding 14 mg (0.033 mmol, 87% yield) of a red solid.

### 15 2.2 Preparation of dibromorhodamine n-butylester

Rhodamine n-butylester (14 mg, 0.033 mmol) was dissolved in absolute ethanol (3 ml), then bromine (0.0036 ml, 0.070 mmol) was added. The mixture was stirred at room temperature for 1 hr. The solvent was evaporated and the crude reaction residue was purified by flash chromatography using  $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$  (85:15) as

WO 96/07431

PCT/CA95/00485

- 17 -

eluant yielding 15.9 mg (0.027 Mol, 83% yield) of a red solid.


<sup>1</sup>H NMR (Varian 300MHz, CD<sub>3</sub>OD)

5 d 8.31 (dd, J=1.7 and 7.5Hz, 1H); 7.84 (M, 2H); 7.46 (dd, J=1.8 and 6.9Hz, 1H); 7.12 (d, J=9.2Hz, 2H); 7.03 (d, J=9.2Hz, 2H); 3.95 (t, J=6.2Hz, 2H); 1.22 (M, 2H); 0.93 (M, 2H); 0.75 (t, J=7.3Hz, 3H).

MS (LR,FAB) m/z: Calculated for C<sub>24</sub>, H<sub>21</sub>N<sub>2</sub>O<sub>3</sub>Br<sub>2</sub>; 543

10 Observed: 543

### 3. Preparation of dibromorhodamine 123



15

To a solution of rhodamine 123 (25 mg, 0.066 mmol) in dry ethanol (1 ml), was added bromine (0.01 ml, 0.19 mmol) and the resulting mixture was stirred at room temperature for 0.5hr. Evaporation of solvent in vacuum provided the crude compound which was purified by flash chromatography using CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH (85:15) as eluant yielding 27.0 mg (0.050 Mol, 77% yield) of a red solid.

20

25 <sup>1</sup>H NMR (Varian 300MHz, CD<sub>3</sub>OD)

d 8.34 (dd, J=1.7 and 7.5Hz, 1H); 7.85 (M, 2H); 7.46 (dd, J=1.7 and 7.2Hz, 1H); 7.10 (d, J=9.2Hz, 2H); 7.01 (d, J=9.2Hz, 2H); 3.64 (s, 3H). 8.3 (d, 1H, 9.1Hz,

WO 96/07431

PCT/CA95/00485

- 18 -

aromatic), 7.9 (m, 2H,aromatic), 7.45 (d, 1H, 9.1Hz, aromatic), 7.0, 7.2 (AB system, 4H, aromatic), 3.64 (s, 3H, OCH<sub>3</sub>).

MS (LR, FAB) m/z: Calculated for C<sub>24</sub>, H<sub>21</sub>N<sub>2</sub>O<sub>3</sub>Br<sub>2</sub>; 501

5 Observed: 501

UV (methanol)/<sub>max</sub>: 510nm

#### Physical and photochemical properties

10 After synthesis, the purity of the preparation of the dyes was assessed by NMR analysis and was shown to be over 95%. Absorption and emission spectra were determined for each dye.

#### Evaluation of cell viability

15 The K562 chronic myelogeneous leukemia cell line (Lozzio,B.B. and Lozzio,C.B. (1979) *Cancer Res.*, 3(6): 363-370) was obtained from the American Type Culture Collection (ATCC, 12301 Parklawn Drive, Rockville, MD 20852 USA) under the accession number F-  
20 10601 R243-CCL. Cultures were maintained at 37°C in a humidified incubator with an atmosphere of 95% air and 5% CO<sub>2</sub>. The culture media (IMDM (Iscove Modified Dulbeco Media) supplemented with 10% fetal bovine serum) were changed bi-weekly and the cells  
25 resuspended at a concentration of 100,000/ml. Cells were shown to be mycoplasma negative by routinely testing at 4 weeks interval.

Before each experiment, cell viability was assessed and 2 X 10<sup>6</sup> viable cells were distributed in  
30 each 15 ml test tube. Cells were then incubated for 1 hour at 37°C, spun down and the cell pellet resuspended in the culture media in the presence or absence of dye. The cells were then incubated for the appropriate time at 37°C, generally 40 minutes, then

WO 96/07431

PCT/CA95/00485

- 19 -

washed twice in PBS (Phosphate Buffer Saline) and resuspended in the culture media. Photodynamic therapy was then applied to the cell culture, immediately or after an incubation period at 37°C. The  
5 cell cultures were kept at 4°C during the application of photodynamic activation.

#### Phototoxicity of 4,5-dibromorhodamine 123

To assess the photochemotherapeutic potential  
10 and the *in vitro* phototoxicity of 4,5-dibromorhodamine 123 (DBR), the leukemic K-562 cell line assay (as described above) was applied. Exposure to 514.5nm radiation from an argon ion laser at 10 J/cm<sup>2</sup> induced  
15 photo toxicity in K-562 cells treated with DBR at a final concentration of 10 µg/ml. DBR was shown to be markedly more phototoxic than rhodamine 123; the increased activity is beleived to be a consequence of increased intersystem crossing of DBR to the triplet manifold via spin orbital-coupling induced by the  
20 heavy atoms. As shown in Fig. 1, dibromorhodamine is extremely phototoxic at doses as little as 1 J/cm<sup>2</sup> and the cell viability drops under 5% in less than 24 hours after irradiation.

#### 25 Phototoxicity of 4,5-dibromorhodamine 110 n-butyl ester

To ascertain the photochemotherapeutic potential of 4,5-dibromorhodamine 110 n-butyl ester (DBBE),  
30 *in vitro* phototoxicity was evaluated in the K-562 cell line procedure described. The cells were incubated with increasing concentrations of DBBE and the cell viability was measured at different time points following photodynamic therapy. The results shown in  
Figs. 2A, 2B and 2C show that a dosage of 10 µg/ml of  
35 the dye and a brief exposure at 0.5 J/cm<sup>2</sup> completely

WO 96/07431

PCT/CA95/00485

- 20 -

suppress cell viability in less than 24 hours after irradiation.

#### **Photo toxicity of Rhodamine B n-butyl ester**

5           The photo toxicity *in vitro* of rhodamine B n-butyl ester (RBBE) was evaluated in the K-562 cell line procedure, in order to assess its photochemotherapeutic potential. Comparison was made to the induced phototoxicity of rhodamine 123 (123RH) and of rhodamine B butyl ester. Cell viability was evaluated 2 and 20 hours after photodynamic therapy. The results shown in Figs. 3A and 3B demonstrate that a dosage of 10 µg/ml of the dye and a photo exposure of 5 J/cm<sup>2</sup> significantly suppress cell viability of K562 cells in less than 20 hours after irradiation. Rhodamine 123 has no effect on cell viability, even at exposures of 10 J/cm<sup>2</sup>.

#### **Phototoxcitivity against bone marrow cultures**

20           It is observed that the photo treatment alone, at energy levels up to 10 J/cm<sup>2</sup>, or the pre-incubation of the cells at saturating concentrations of the dyes did not affect neither the establishment of the long term culture nor the formation in semi solid assays of cellular colonies issued from the multiplication and differentiation of committed progenitors present in the bone marrow (colony forming units-erythrocytes (CFU-E), blast forming units-erythrocytes (BFU-E), colony forming units-granulocytes, macrophages, (CFU-G-M)). However, as reported for rhodamine 123, the LTC (Long Term Culture) establishment is more sensitive to the dyes but the number of viable committed precursor and stem cells remains unaffected. Photodynamic therapy with rhodamine 123, rhodamine B n-butyl ester and 4,5-dibromorhodamine n-butyl ester

WO 96/07431

PCT/CA95/00485

- 21 -

minimally impaired the establishment of normal mouse long term culture of bone marrow and the formation of hematopoietic colonies in semi-solid assays. This is in agreement with results obtained previously in other  
5 laboratoties using rhodamine 123.

Conventional approaches for the treatment of cancer such as radiotherapy and intensive chemotherapy are limited by their intrinsic toxicity and myelosuppressive effects. The introduction of  
10 allogeneic and autologous bone marrow transplantation have allowed the administration of marrow ablative chemotherapy and radiotherapy to patients whose malignancies cannot be cured with less aggressive measures. However, allogeneic bone marrow  
15 transplantation is not widely accessible to patients because of the lack of suitable donnors and the onset of graft-versus-host disease in recipients. To overcome these limitations and to expand the number of patients and age limit for intensive curative therapy,  
20 the potential benefit of *in vitro* bone marrow purging and autologous bone marrow transplantation has become widely acknowledged.

In an effort to develop new anti-neoplastic drugs that would allow selective destruction of  
25 leukemic malignant cells, new dye molecules have been prepared and tested as possible new photosensitizers, useful for the photodynamic therapy of leukemias and metastatic cancers. Three new photosensitizers of the pyrylium family were prepared and there is provided  
30 evidence for their potential use in the photodynamic treatment of cancers and the leukemias.

The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to  
35 limit its scope.

WO 96/07431

PCT/CA95/00485

- 22 -

**EXAMPLE I****Method of treatment of leukemias****1. Diagnostic procedures**

5       Diagnosis of chronic myelogenous leukemia (CML) will be established using one or more of the following procedures on blood or bone marrow cells:

- a) conventional cytogenetics studies with identification of Ph 1+ metaphases harbouring the t(9:22);
- 10       b) fluorescent *in situ* hybridization for the detection of the bcr/abl rearrangement; and
- c) Southern blot analysis for the detection of a rearranged ber fragment or PCR-RT for the detection of chimeric ber/abl messenger RNA.

15

**2. Bone marrow harvesting**

After diagnosis, bone marrow (BM) or peripheral blood (PB) derived hemopoietic stem cells will be harvested using previously described procedures for the autologous marrow transplantation in cancer therapy (reviewed by Herzig GP, (1981) *Prog. Hematol.*, 12:1). Hemopoietic stem cells collected for autograft will be immediately treated *ex vivo* as described below.

25

**3. In vitro purging of leukemia**

*Ex vivo* treatment will consist of short-term incubation or BM of PB stem cells with one or several of the selected photoactive compounds. Duration of incubation, cell concentration and drug molarity will be determined for each patient using an aliquot of the harvested cell population. Excess of dyes will be removed by cell washes with sterile dye free medium supplemented with 2% autologous serum. Cells will

35       next be exposed to radiant energy of sufficient



WO 96/07431

PCT/CA95/00485

- 23 -

intensities to effect photodynamic purging of leukemia cells. Efficacy of the photodynamic purging procedure will be verified on an aliquot of the treated cell population, before cryopreservation and/or re-infusion to the patient is performed. Until re-infusion to the patient, the cells will be cryopreserved in 10% dimethyl sulfoxide (DMSO) - 90% autologous serum medium, at -196°C in the vapour phase of liquid nitrogen.

#### 4. Systemic treatment of patients

Following stem cell harvest, patient will be either treated with conventional regimens until autografting is clinically indicated or immediately submitted to dose-intensive chemotherapy and total body irradiation where indicated.

#### 5. Autologous stem cell transplantation

Following appropriate treatment of the patient by high-dose chemotherapy and irradiation and at the appropriate clinical moment, cryopreserved marrow or peripheral blood stem cells will be rapidly thawed and diluted in medium containing 25 UI DNase ml<sup>-1</sup> to minimize clumping. A minimum of  $2 \times 10^7$ /kg nucleated cells with 85% to 95% viability as measured by Trypan™ blue exclusion will be returned to the patient.

### EXAMPLE II

#### Method of treatment of malignancies

##### 1. Diagnostic procedures

Diagnosis of malignancies will be established using conventional histopathological examination of the primary tumor. Detection of marrow involvement by neoplastic cells will be achieved by direct histological examination and ancillary procedures

WO 96/07431

PCT/CA95/00485

- 24 -

where indicated (i.e. immuno-peroxydase, immunohistochemical, tumor markers and hybridization studies).

5    2.    **Bone marrow harvesting**

After diagnosis, bone marrow (BM) or peripheral blood (PB) derived hemopoietic stem cells will be harvested using previously described procedures for the autologous marrow transplantation in cancer  
10 therapy (reviewed by Herzig GP, (1981) *Prog. Hematol.*, 12:1). Hemopoietic stem cells collected for autograft will be treated immediately ex vivo as described below.

15    3.    **In vitro purging of leukemia**

Ex vivo treatment will consist of short-term incubation of BM or PB stem cells with one or several of the selected photoactive compounds. Duration of incubation, cell concentration and drug molarity will  
20 be determined for each patient using an aliquot of the harvested cell population. Excess of dyes will be removed by cell washes in sterile dye free medium supplemented with 2% autologous serum. Cells will next be exposed to radiant energy of sufficient  
25 intensities to effect photodynamic purging of leukemia cells. Whenever a sensitive molecular marker is available, an aliquot of the treated cell population will be tested for the detection of residual neoplastic cells before cryopreservation and/or re-  
30 infusion to the patient is attempted. The cells will be cryopreserved in 10% dimethyl sulfoxide (DMSO) - 90% autologous serum medium, at 196°C in the vapour phase of liquid nitrogen.

WO 96/07431

PCT/CA95/00485

- 25 -

4.       **Systemic treatment of patients**

Following stem cell harvest, patient will be either treated with conventional regimens until autografting is clinically indicated or immediately submitted to dose-intensive chemotherapy and total body irradiation where indicated.

5.       **Autologous stem cell transplantation**

Following high-dose chemotherapy and irradiation cryopreserved marrow or peripheral blood stem cells will be rapidly thawed and diluted in medium containing 25 UI DNase Ml<sup>-1</sup> to minimize clumping. A minimum of  $2 \times 10^7$ /kg nucleated cells with 85% to 95% viability as measured by Trypan™ blue exclusion will be returned to the patient.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

**WE CLAIM:**

1. Photoactivable rhodamine derivatives for enhancing high quantum-yield production and singlet oxygen generation upon irradiation while maintaining desirable differential retention of rhodamine between normal and cancer cells, said derivatives are selected from the group consisting of 4,5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrochloride); 4, 5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid ethyl ester hydrochloride); 4, 5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid octyl ester hydrochloride); 4,5-dibromorhodamine 110 n-butyl ester (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride); Rhodamine B n-butyl ester (2-(6-ethyl amino-3-ethyl imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride); and photoactivable derivatives thereof; whereby photoactivation of said derivatives induces cell killing while unactivated derivatives are substantially non-toxic to cells.

2. Use of the photoactivable derivatives of claim 1 for the photodynamic therapy of a cancer patient by destroying human cancer cells, wherein appropriate intracellular levels of said derivatives are achieved and irradiation of a suitable wavelength and intensity is applied.

3. A method for the photodynamic therapy of a patient suffering from leukemias, disseminated multiple myelomas or lymphomas, which comprises the steps of:

a) harvesting said patient's human bone marrow;

WO 96/07431

PCT/CA95/00485

- 27 -

- b) purging of the bone marrow of step a) by photodynamic therapy using a therapeutic amount of a photoactivable derivative of claim 1 under irradiation of a suitable wavelength; and
- c) performing autologous stem cell transplantation using the purged bone marrow of step b).

4. The method of claim 3, wherein said purging of step b) further comprises intensive chemotherapy and total body irradiation (TBI) procedures.

5. A method for *in vitro* purging of the human bone marrow containing metastasis of solid tumors, selected from the group consisting of metastasis of breast, lung, prostatic, pancreatic and colonic carcinomas, disseminated melanomas and sarcomas, wherein surgical excision or debulking can be achieved, which comprises the steps of:

- a) harvesting said patient's human bone marrow;
- b) purging of the bone marrow of step a) by photodynamic therapy using a therapeutic amount of a photoactivable derivative of claim 1 under irradiation of a suitable wavelength; and
- c) performing autologous stem cell transplantation using the purged bone marrow of step b).

6. The method of claim 5, wherein said purging of step b) further comprises intensive chemotherapy and total body irradiation (TBI) procedures.

7. A method for the photodynamic therapy of a cancer patient, which comprises administering to a patient a therapeutically acceptable intracellular level of a photoactivable derivative of claim 1 and

WO 96/07431

PCT/CA95/00485

- 28 -

subjecting said patient to a irradiation of a therapeutically suitable wavelength.

8. The method of claim 7, wherein said photoactivable derivative is administered by instillation, injection, bloodstream diffusion at the tumor sites directly accessible to light emission or tumor sites accessible to laser beams using rigid or flexible endoscopes.

9. The method of claim 8, wherein said laser-accessible tumor site is selected from the group consisting of urinary bladder, oral cavity, esophagus, stomach, lower digestive tract, upper and lower respiratory tract.



10. A method for the treatment of leukemias in a patient, which comprises the steps of:

- a) purging of cancerous clones from the bone marrow of said patient;
  - b) subjecting said purged clones of step a) to a photodynamic treatment using a therapeutical amount of the photoactivable derivatives of claim 1 under irradiation of a suitable wavelength for the selective destruction of leukemic cells without affecting the normal cells of the patient;
  - c) administering said treated clones of step b) to the patient;
- thereby causing no systemic toxicity for the patient.

WO 96/07431



PCT/CA95/00485

1/3



WO 96/07431

PCT/CA95/00485


*Fig. 2B**Fig. 2c*




WO 96/07431

PCT/CA95/00485

3/3

*Fig. 3A*

- 1- CONTROL, 0J/CM2
- 2- CONTROL, 5J/CM2
- 3- 123RH, 0J/CM2
- 4- 123RH, 5J/CM2
- 5- DBR+RBBE, 0J/CM2
- 6- DBR+RBBE, 5J/CM2
- 7- RBBE, 0J/CM2
- 8- RBBE, 5J/CM2
- 9- RBOE, 0J/CM2
- 10- RBOE, 5J/CM2

*Fig. 3B*

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 95/00485

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 A61K41/00 C07D311/82

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE BIOSIS          BIOSCIENCES INFORMATION SERVICE,          PHILADELPHIA, PA, US          AN=95:331441,          see abstract          &amp; 23RD ANNUAL MEETING OF THE AMERICAN          SOCIETY FOR PHOTOBIOLOGY, WASHINGTON,          D.C., USA, PHOTOCHEMISTRY AND PHOTOBIOLOGY          ,          vol. 61, no. 5, 17 - 22 June 1995          page 29S          PAL P. ET AL. 'PHOTOXICITY OF BROMINE          SUBSTITUTED DYES: SYNTHESIS, PHOTOPHYSICAL          PROPERTIES.'</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1,2,7-9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

5 December 1995

Date of mailing of the international search report

20.12.1995

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+ 31-70) 340-3016

Authorized officer

Berte, M

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 95/00485

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 111, no. 11, 11 September 1989 Columbus, Ohio, US; abstract no. 92985, PORCELLINI, ADOLFO ET AL 'Limiting dilution analysis for detection of residual leukemic cells after bone marrow combined decontamination with mafosfamide followed by merocyanine-540-mediated photosensitization' see abstract & INT. J. CELL CLONING (1989), 7(4), 223-31 CODEN: IJCCE3;ISSN: 0737-1454, 1989 ---	1,5,6
Y	DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US AN=93:22793, see abstract & 34TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY, SAN DIEGO, CALIFORNIA, USA, INT. J. RADIAT. ONCOL. BIOL. PHYS., vol. 24, no. 1, 9 - 13 November 1992 page 207 WONG J.R. ET AL. 'A NOVEL METHOD OF PURGING CARCINOMA CONTAMINATED BONE MARROW USING THE LIPOPHILIC CATION RHODAMINE 123' ---	1-10
A	CHEMICAL ABSTRACTS, vol. 116, no. 15, 13 April 1992 Columbus, Ohio, US; abstract no. 147035, HAGHIGHAT, SHAGHAYEGH ET AL 'Laser dyes for experimental phototherapy of human cancer: comparison of three rhodamines' see abstract & LARYNGOSCOPE (1992), 102(1), 81-7 CODEN: LARYA8;ISSN: 0023-852X, 1992 ---	1-10
Y	CHEMICAL ABSTRACTS, vol. 116, no. 15, 13 April 1992 Columbus, Ohio, US; abstract no. 146920, BUNTING, JAMES R. 'A test of the singlet oxygen mechanism of cationic dye photosensitization of mitochondrial damage' see abstract	1-10
X	& PHOTOCHEM. PHOTOBIOLOG. (1992), 55(1), 81-7 CODEN: PHCBAP;ISSN: 0031-8655, 1992 ---	1
	--- -/--	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/CA 95/00485

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 112, no. 5, 29 January 1990 Columbus, Ohio, US; abstract no. 32723, GULLIYA, K. 'An in vitro model of autologous bone marrow purging for multiple myeloma and lung carcinoma cells by laser photoradiation therapy' see abstract & CANCER J. (1989), 2(11), 378-82 CODEN: CANJEI, 1989	
X	--- DATABASE BEILSTEIN BEILSTEIN REGISTRY NUMBER=1334284, see abstract & ZH. ANAL. KHIM., vol. 15, 1960 page 523 KUONIZOW ET AL.	1
P,X	--- GB,A,2 283 744 (MOLECULAR PROBES INC) 17 May 1995 see claims -----	1

## INTERNATIONAL SEARCH REPORT

international application No.

PCT/CA95/00485

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 3-10 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**